Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Current rofecoxib use was associated with a higher risk of acute myocardial infarction or admission for heart failure compared to celecoxib.

COX-2 Inhibitor Controversy